Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
The original release is unavailable here.
Story so far
- Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
- Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
- Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market
Earlier from Gelteq
- Gelteq to Present at Investor Summit Virtual on December 9, 2025
- Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
- Annual Report for Fiscal Year Ending June 30, 2025 (Form 20-F)
- Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
- Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
Later from Gelteq
- Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China
- Gelteq Furthers Asia Presence Through Partnership with Hong Kong Flag Football Program
- Gelteq Announces Positive Preclinical Results Showing Increased Medicinal Cannabinoid Absorption Using Its Oral Gel Delivery Platform
- Gelteq and Healthy Extracts to Expand Gel-Based Nutrition Technologies with New Strategic Manufacturing & Commercial Partnership
- Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
Follow Gelteq into a list and get an email when it puts out news.
Follow Gelteq